or Connect
HotStockMarket › Forums › HSM Stock Forum › Trade Journals & Stock Tips › angrysky's sub penny storm thought share
New Posts  All Forums:Forum Nav:

angrysky's sub penny storm thought share - Page 7

post #121 of 734
Thread Starter 

On March 19, 2010, Randall Reneau was appointed to the board of directors (the “Board”) of American Energy Fields, Inc. (the “Company”) and named as Chairman of the Board.

On March 19, 2010, the Company and Mr. Reneau entered into an agreement (the “Agreement “) whereby, in consideration for his services as Chairman of the Board, Mr. Reneau shall receive a monthly cash payment of $3,000 and an aggregate of 350,000 restricted shares of the Company’s common stock upon execution of the Agreement. Additionally, Mr. Reneau shall receive an aggregate of 750,000 stock options with an exercise price of $0.15 per share, which shall vest 150,000 shares every six months for a total vesting period of thirty (30) months.

Mr. Reneau is registered as a Certified Professional Geologist with over 35 years of experience in mineral exploration and project management in the United States, Mexico, Brazil, and West Africa. Mr. Reneau was the Co-Founder and currently resides as the Chairman of the Board of Strategic American Oil Corporation (SGCA), a publicly listed oil and gas exploration and production company based out of Corpus Christi, Texas. He served Strategic American Oil as President and CEO from 2007 to 2009. Mr. Reneau was also recently the Co-Founder, Principle Geologist, Chief Exploration Officer For Uranium Energy Corp. (UEC) an Amex listed company from January 2004 to July 2007. While there, he was the initial driving force who developed the uranium property portfolio. He has significant experience exploring for uranium in the United States, specifically in Texas, Arizona, New Mexico, and Wyoming, the states known to hold the largest uranium reserves. He extensively explored these states while employed in a senior position for Conoco Uranium, a subsidiary of Conoco Ltd., and Wold Nuclear, a privately-held company. Mr. Reneau holds licenses to practice geology in the states of Texas, Washington and Alaska. From December 2003 to December 2004, Mr. Reneau served as Chief Geologist for Oromex Resources in Durango, Mexico. From 1997 to December 2003, Mr. Reneau served as senior consulting geologist for AZCO Mining, Inc., managing exploration projects in Mali, West Africa and Sonora, Mexico. From 1990 to 1999, Mr. Reneau served as Principal Geologist for Reneau and Associates, a Geo-Environmental firm. From 1988 to 1990, Mr. Reneau was employed as a senior consulting geologist with Western Mining Corporation's Canadian subsidiary, Westminer Canada. Mr. Reneau's role at Westminer Canada included mineral exploration in West Africa. Mr. Reneau served as President of Reneau Exploration and Development Company, Inc. ("REDCO") from 1980 to 1988. REDCO drilled and operated wells in Stephens County, Oklahoma and Navarro, Milam, Wilson and Guadalupe Counties in Texas. Mr. Reneau has a B.A. in Geology from Central Washington University and an M.S. in Environmental Engineering from Kennedy-Western University.

Mr. Reneau has not been involved in an y transaction with the Company that would require disclosure under Item 404(a) of Regulation S-K.

post #122 of 734
Thread Starter 
AspenBio Completes Patient Enrollment of AppyScore Clinical Trial to Support FDA 510(k) Submission

CASTLE ROCK, CO., March 23, 2010 -- AspenBio Pharma, Inc. (Nasdaq: APPY) has completed patient enrollment for its AppyScore™ pivotal clinical trial designed to evaluate 800 patients suspected of having acute appendicitis. The study has now advanced to the data analysis phase.

The company estimates approximately six to eight weeks will be required to independently review and validate final clinical and assay data and statistical analysis. Upon completion of this analysis the data will then be included in the FDA 510(k) package. The company continues to plan on completing the FDA 510(k) submission in the second quarter of 2010.

“This broad-based national trial, which collected blood samples from patients at thirteen major academic hospitals, represents the most expansive and tightly controlled trial ever conducted for AppyScore,” said Dr. Robert Caspari, AspenBio Pharma’s COO and CMO. “While at this point there can be no assurance the trial data will be sufficient to achieve FDA clearance of AppyScore, we believe we are well positioned to demonstrate the benefits AppyScore brings to the evaluation of patients suspected of having acute appendicitis in the emergency department setting.”

Acute appendicitis occurs in 7% of the US population and is the most common reason for a child to need emergency abdominal surgery. In addition to helping improve the evaluation of appendicitis, the company believes AppyScore has the potential to reduce the use of computed tomography (commonly referred to as “CT”) scans and the associated radiation exposure risk for patients, while also reducing health care costs.

About AspenBio Pharma, Inc.
AspenBio Pharma, Inc. (NASDAQ: APPY) is developing and commercializing innovative products that address unmet diagnostic and therapeutic needs. The company’s lead product candidate, AppyScore, is a novel blood-based diagnostic test that evaluates patients suspected of having acute appendicitis and addresses the difficult challenge of properly diagnosing appendicitis in the hospital emergency department setting. For more information, please visit www.aspenbiopharma.com.

Forward-Looking Statements
This news release includes "forward-looking statements" of AspenBio Pharma, Inc. ("APPY") as defined by the Securities and Exchange Commission ("SEC"). All statements, other than statements of historical fact, included in the press release that address activities, events or developments that APPY believes or anticipates will or may occur in the future are forward-looking statements. These statements are based on certain assumptions made based on experience, expected future developments and other factors APPY believes are appropriate in the circumstances. Such statements are subject to a number of assumptions, risks and uncertainties, many of which are beyond the control of APPY. Investors are cautioned that any such statements are not guarantees of future performance. Actual results or developments may differ materially from those projected in the forward-looking statements as a result of many factors, including statements regarding actual trial results, the ability to successfully complete the clinical trial data assessments required for FDA submission, obtain FDA approval for, cost effectively manufacture and generate revenues from the appendicitis test and other new products, execute agreements required to successfully advance the company's objectives, retain the scientific management team to advance the products, overcome adverse changes in market conditions and the regulatory environment, fluctuations in sales volumes, obtain and enforce intellectual property rights, and realization of intangible assets. Furthermore, APPY does not intend (and is not obligated) to update publicly any forward-looking statements. The contents of this news release should be considered in conjunction with the warnings and cautionary statements contained in APPY's recent filings with the SEC.

For more information contact:
AspenBio Pharma, Inc.
Gregory Pusey, Vice President and Vice Chairman
Tel 303-722-4008

Investor Relations:
Liolios Group, Inc.
Geoffrey Plank or Ron Both
Tel 949-574-3860

post #123 of 734
Thread Starter 
AspenBio Pharma, Inc. Names Steve Lundy As Chief Executive Officer
8:30am EDT
AspenBio Pharma, Inc. announced that Steve Lundy has joined the Company as Chief Executive Officer and will become a member of the Board of Directors. The addition of Mr. Lundy is part of succession and organizational planning that was initiated in the latter half of 2009. Daryl Faulkner, who served as Interim Chief Executive Officer in 2009 will relinquish that role but will continue as Executive Chairman of the Company. - - - - - (repeated)
AspenBio Pharma, Inc. Enters Into Development and Supply Agreement For AppyScore Cassette With BBInternational
Wednesday, 10 Mar 2010 08:30am EST
AspenBio Pharma, Inc. announced that it has entered into a strategic manufacturing relationship with BBInternational (BBI) to complete commercial development and manufacture of the AppyScore consumable test cassette. The ELISA format of the AppyScore Test is currently in clinical trials for clearance by the FDA and is designed to aid in the evaluation of patients suspected of having acute appendicitis. In parallel with development of the ELISA format, the company has been developing a cassette and instrument format of the test, which will require separate regulatory clearance prior to commercialization. Under the terms of the agreement, BBI will manufacture the lateral flow test cassette and associated reagents (the Cassette) and will be responsible for providing the required manufacturing capacity and quality standards necessary to meet global market demand. - - - - - (repeated)
AspenBio Pharma, Inc. Reports On AppyScore Supplemental Clinical Trial Interim Analysis And Provides Guidance On FDA
Tuesday, 9 Feb 2010 04:05pm EST
AspenBio Pharma, Inc. announced conclusions from its pre-planned, independent, interim analysis of the Company's ongoing supplemental clinical trial of AppyScore, the first blood-based test designed to aid in the evaluation of patients suspected of having acute appendicitis, and outlined next steps for its AppyScore 510(k) filing with the U.S. Food and Drug Administration (FDA). Based on the interim analysis, the trial, currently with over 600 patients enrolled, will continue enrollment to approximately 800 patients with completion anticipated in March of 2010. Given the time estimate to complete the current trial and related data analysis, the Company has withdrawn its 510(k) on file with the FDA and will submit a new 510(k) with full results from the ongoing clinical trial. This clinical trial is statistically sized to stand alone and thereby becomes the pivotal trial to support the new 510(k) submission. - - - - - (repeated)
post #124 of 734
Thread Starter 
The common stock of Axiologix Education Corporation (the “Registrant”) became eligible for trading on the FINRA-operated Over-the-Counter Bulletin Board (“OTCBB”) when the market opened on Tuesday, March 23, 2010. The shares of the Registrant will trade under the ticker symbol “AXLX.OB”.

The OTCBB is a regulated quotation service that displays real-time quotes, last-sale prices and volume information for over-the-counter equity securities. OTC securities are traded by a community of market makers that enter quotes and trade through a sophisticated computer network. Information on the OTCBB can be found at www.otcbb.com.


Pursuant to the requirements of the Securities Exchange Act of 1934, the Registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.



Date: March 24, 2010

By: /s/ John P. Daglis

John P. Daglis, President

will this start showing a chart?
post #125 of 734
Thread Starter 
In connection with the corporate name change, the Company’s stock ticker symbol has changed from “BLSW” to “BLIN” on the NASDAQ Capital Market, effective as of March 23, 2010. Stockholders do not need to exchange stock certificates in connection with the corporate name change and ticker symbol change

Bridgeline is a developer of web application management software and award-winning interactive business technology solutions that help organizations optimize business processes. The iAPPS Product Suite is an innovative SaaS solution that unifies Content Management, Analytics, eCommerce, and eMarketing capabilities – enabling business users to swiftly enhance and optimize the value of their web properties.

Combined with award-winning interactive technology services by Microsoft Gold Certified development teams, Bridgeline helps customers to cost-effectively maximize the value of their rapidly changing web applications. Bridgeline's teams of developers specialize in web application development, usability engineering, SharePoint development, rich media development, and search engine optimization.

Bridgeline is headquartered near Boston with additional locations in Atlanta, Chicago, Cleveland, Denver, New York, Washington, D.C., and Bangalore, India. Bridgeline Software currently has over 600 customers ranging from middle market organizations to divisions within Fortune 1,000 companies that include: Healthcore, The Bank of New York Mellon, Marriott International, Berkshire Life, PODS, Honeywell, Budget Rental Car, Washington Redskins, AARP, National Financial Partners, The Packard Foundation, DTCC, Cadaret, Grant & Co., National Insurance Crime Bureau, the American Academy of Pediatrics, and Shaw Industries (a Berkshire Hathaway company). To learn more about Bridgeline, please visit www.bridgelinesw.com.

CONTACT: Bridgeline Software, Inc.
Brian Bolton, Vice President of Marketing

WOBURN, Mass., March 2, 2010 (GLOBE NEWSWIRE) -- Bridgeline Software, Inc. (Nasdaq:BLSW), a developer of unified web application management software and award-winning interactive technology solutions, today announced that it has been named one of the 100 Companies That Matter in Knowledge Management by KMWorld Magazine. KMWorld is the leading information provider serving the Knowledge, Document and Content Management systems market with over 45,000 subscribers. Bridgeline is the developer of iAPPS Content Manager, the flagship web content management system within the iAPPS Product Suite, an innovative solution that deeply unifies Content Management, Analytics, eCommerce, and eMarketing capabilities - enabling users to swiftly enhance and optimize the value of their web properties. The state-of-the art iAPPS architecture provides customers with the options of either a SaaS subscription deployment model or traditional perpetual licensing option.

To approve the amendment to the Bridgeline Software, Inc. Amended and Restated Stock Incentive Plan to increase the number of shares of Common Stock available for issuance upon exercise of options granted under the Plan from 2,000,000 to 2,400,000 shares. The votes cast were as follows:

Votes For Votes Against Abstained Broker Non-Votes
5,314,745 1,012,246 140 2,940,338

post #126 of 734
Thread Starter 

Notice of Annual Meeting

To Be Held on March 30, 2010

Our Board of Directors unanimously adopted, subject to stockholder approval, an amendment to Article IV of our Amended and Restated Certificate of Incorporation to increase the number of shares of common stock that are authorized to be issued from 250,000,000 to 400,000,000 shares and directed that the proposed amendment be submitted to a vote of our stockholders at the Annual Meeting. No change will be made to the number of shares of Series B common stock and shares of preferred stock that are authorized for issuance. The full text of the proposed amendment to the first paragraph of Article IV of our Amended and Restated Certificate of Incorporation is as follows:

“The total number of shares of all classes of capital stock which the Corporation shall have the authority to issue is four hundred twenty million (420,000,000) shares, consisting of four hundred million (400,000,000) shares of common stock with a par value of $0.001 per share (the “common stock”) and twenty million (20,000,000) shares of preferred stock with a par value of $0.001 per share (the “Preferred Stock”).”

The Board of Directors believes that there are a number of important business reasons for increasing the number of shares of common stock the Company is authorized to issue.

Under our Amended and Restated Certificate of Incorporation, as presently in effect, the Company has 270,000,000 shares of capital stock authorized for issuance, consisting of 250,000,000 shares of common stock, $0.001 par value, and 20,000,000 shares of preferred stock, $.001 par value. Of the 250,000,000 shares of common stock, 2,000,000 shares were previously designated as Series B nonvoting shares. As of February 1, 2010, we had a total of 145,987,459 shares of common stock issued and outstanding (which includes 999,969 shares of Series B nonvoting common stock), and no shares of preferred stock issued and outstanding. As of February 1, 2010, we had reserved 79,585,930 shares of our common stock for future issuance pursuant to (i) our 2002 Stock Incentive Plan, (ii) exercise of outstanding common stock purchase warrants, (iii) conversion of convertible debt, and (iv) the definitive Arrangement Agreement between the Company and Schneider Power, Inc., which was announced on November 23, 2009 (the “Arrangement Agreement”) and is anticipated to close in the first half of the 2010 calendar year, subject to the terms and conditions contained in the Arrangement Agreement. Accordingly, as of February 1, 2010, the number of authorized shares of common stock that had not been reserved for future issuance was 24,426,611 (which includes 1,000,031 shares of Series B nonvoting common stock).

However, the 79,585,930 shares reserved for future issuance as of February 1, 2010 did not include: (i) approximately 12,800,000 shares potentially issuable to our lender in payment of approximately $9,100,000 due under two demand notes (the “Demand Notes”) which, when demand for payment is made, we, in our sole discretion, can elect to pay using shares of our common stock provided that certain conditions are met, and (ii) approximately 14,100,000 shares potentially issuable to an affiliate of our lender pursuant to a $10,000,000 unconditional commitment we received from our lender (the “Commitment Letter”) that expires on March 31, 2011.

Approval of this Proposal 3 will provide the Company with flexibility to use its common stock for a variety of business and financial purposes. Most importantly, it will allow the Company to raise needed working capital and to use shares of common stock to pay the principal amount owed under the Demand Notes. Approval of this Proposal 3 will also allow the Company to use its common stock to expand its business through acquisitions, provide equity incentives to officers, directors and employees of the Company, and ensure that the full value under the Commitment Letter is available to us if needed. Further, the increase will enable the Company to promptly take advantage of market conditions and the availability of favorable business opportunities without the delay and expense associated with holding a special meeting of stockholders.

If this Proposal 3 is approved, the additional shares of our common stock so authorized may be issued from time to time upon authorization of our Board, without further approval by our stockholders, unless otherwise required by applicable law or stock exchange requirements, and for such consideration as our Board may determine and as may be permitted by applicable law. The additional shares of common stock would have rights identical to the rights of our current common stockholders. The authorization of additional shares of our common stock pursuant to this proposal will have no dilutive effect upon the proportionate ownership and voting power of our current stockholders. However, the actual issuance of additional common stock in the future would dilute each existing stockholder’s proportionate ownership and voting power. The Company does not currently have any specific arrangements or understandings, either written or oral, to issue any of the additional authorized shares of capital stock. However, the Company does plan to raise additional capital in the near term and plans to do so by issuing shares of its common stock.

If this Proposal 3 is not approved, it would have a material adverse effect on the Company. The Company’s ability to raise equity or debt capital on reasonable terms, if at all, and pay the amount owed to our lender under the Demand Notes would be severely limited...

post #127 of 734
Thread Starter 

Directors Whose Terms Continue Until the Annual Meeting for Fiscal Year 2010

Alan P. Niedzwiecki, age 52, has served as our President and on our Board of Directors since February 2002, and was appointed as our Chief Executive Officer in August 2002. Mr. Niedzwiecki served as our Chief Operating Officer from November 2001 until he was appointed as our Chief Executive Officer in August 2002. From October 1999 to November 2001, Mr. Niedzwiecki served as our Executive Director of Sales and Marketing. From February 1990 to October 1999, Mr. Niedzwiecki was President of NGV Corporation, an engineering and marketing/commercialization consulting company. Mr. Niedzwiecki has more than 25 years of experience in the alternative fuels industry in product and technology development and commercialization relating to mobile, stationary power generation and refueling infrastructure solutions. Mr. Niedzwiecki is a graduate of Southern Alberta Institute of Technology. Mr. Niedzwiecki also serves on the board of directors of Fisker Automotive, Inc. (“Fisker Automotive”) and on the board of directors of Advanced Lithium Power Inc. (“ALP”).

Dale L. Rasmussen, age 60, has served as a member of our Board of Directors since October 2000, and was appointed as Chairman of the Board in February 2002. On May 1, 2006, Mr. Rasmussen became a full time employee of the Company. His areas of responsibility include acquisitions, joint ventures, strategic alliances and investor and stockholder relations. Mr. Rasmussen was the Senior Vice President and Secretary of IMPCO Technologies, Inc., a Delaware corporation, from 1989 through 2005. Prior to joining IMPCO, Mr. Rasmussen was a commercial banker for twelve years and was responsible for managing the bank’s investment portfolio and branch and corporate development. Mr. Rasmussen is a graduate of Western Washington University and Pacific Coast Banking School, University of Washington. Mr. Rasmussen also served as Chairman of the Board for Fisker Automotive from November 2007 until January 2010, and currently serves on the board of directors of ALP.

Directors Whose Terms Continue Until the Annual Meeting for Fiscal Year 2011

Paul E. Grutzner, age 44, has served as one of our directors since July 2005. Mr. Grutzner founded ClearPoint Financial, LP, an independent pension consulting firm in 2002, and currently serves as its Managing Partner. Prior to founding ClearPoint Financial, LP, Mr. Grutzner held positions consulting on retirement plans with RBC Dain Rauscher and CIBC Oppenheimer. He received a B.S. in Agricultural Economics and Sociology from the University of Wisconsin, Madison.

Brian A. Runkel, age 48, has served as one of our directors since July 2002. Since 1993, Mr. Runkel has served as President of Runkel Enterprises, an environmental consulting firm. Mr. Runkel also serves as



Table of Contents
Executive Director of the California Environmental Business Council, a non-profit trade and business association representing the California environmental technology and services industries. He received a B.A. in International Relations from George Washington University, and a J.D. from Harvard Law School.

Carl E. Sheffer, age 64, has served as one of our directors since March 2005. Mr. Sheffer is President of Sheffer Enterprises, LLC, a consulting organization focused on the automotive industry, and has over 35 years of experience in the automotive industry. Prior to forming Sheffer Enterprises, Mr. Sheffer was Vice President, OEM Relations, for the Specialty Equipment Market Association (“SEMA”). During his 8 1/2 years with SEMA, Mr. Sheffer was responsible for all of the association’s interactions with the original equipment manufacturers (OEMs), including trade show participation, technology transfer programs, new vehicle measuring sessions and various dealer relations initiatives. Between 1972 and 1999, Mr. Sheffer held a variety of roles in human resources management, manufacturing, public relations and public policy for General Motors Corporation. Mr. Sheffer received a B.S. in business administration from Central Michigan University and a Master’s degree from Oakland University

post #128 of 734
Thread Starter 
Prior 2 posts go with this-


Shiny car- and a slick presentation



Quantum Fuel Systems Technologi(NasdaqGM: QTWW)
After Hours: 0.00 N/A (N/A) 7:00pm ET

Last Trade: 0.68
Trade Time: Mar 25
Change: 0.00 (0.00%)
Prev Close: 0.68
Open: 0.68
Bid: N/A
Ask: 1.59 x 1000
1y Target Est: 2.08
Day's Range: 0.66 - 0.70
52wk Range: 0.60 - 1.77
Volume: 879,013
Avg Vol (3m): 1,940,260
Market Cap: 99.78M
P/E (ttm): N/A
EPS (ttm): -0.38
Div & Yield: N/A (N/A)
post #129 of 734
Thread Starter 
ATLANTA, Mar 26, 2010 (GlobeNewswire via COMTEX) -- Dutch Gold Resources, Inc. (Pink Sheets: DGRI) (the "Company") (http://dutchgold.com) is pleased to announce that its publicly traded subsidiary, Aultra Gold, Inc. /quotes/comstock/11k!agdi (AGDI 0.02, +0.01, +114.29%) has consummated its strategy to acquire Shamika Gold, Inc. ("SGI"), a spinoff from Shamika Resources, Inc., with significant mineral holdings in the Democratic Republic of the Congo. The transaction was consummated as a reverse acquisition and after a name change to Shamika 2 Gold, Inc., Aultra Gold will be the surviving company.

Shamika Gold, Inc. has significant holdings in the Kilo Moto Greenstone Belt, where over thirty international mining companies have begun exploration and development. SGI has property that is surrounded by Kilo Goldmines, and is located near projects which are controlled by Rangold Resources, Ltd. Rangold and AngloGold-Ashanti have announced their interest in the area in October of 2009.

Robert Vivian, founder of Shamika Resources, was appointed as the new CEO of Aultra Gold, Inc. Mr. Vivian stated, "We are pleased to announce that our spinoff of the high potential gold properties has been completed. The Company is pleased to enter the public capital markets through Dutch Gold's subsidiary. Our management team and directors are excited to deliver value to our shareholders through our projects in the Democratic Republic of the Congo."

"We are particularly pleased with the transaction," commented Daniel Hollis, Chairman and CEO of Dutch Gold. He explained, "Shamika Gold, Inc. has quality properties, quality management and institutional investors from the parent company Shamika Resources. We believe that SGI's management will drive value for their shareholders and ours. Shamika's plan to drive near term, small scale production with exploration and development simultaneously makes great sense." Mr. Hollis added, "The Kilo Moto Greenstone Belt is one of the most promising areas in the world right now. For both major companies and junior companies like SGI, there is tremendous opportunity. The value of the Rangold-Moto Gold transaction was approximately US$500 Million. The lesser developed neighbor, Kilo Gold has achieved a market capitalization in excess of US$50 Million within a relatively short period of time. We wish our partners at Shamika Gold similar success, particularly given their focus on near-term production."

About Dutch Gold Resources:

Dutch Gold Resources, Inc. is engaged in the production and development of gold reserves in North America. The company's strategy is to focus on overlooked resources that can be quickly and cost-efficiently brought into production, and to seek out potentially significant exploration targets in high value geographies. The Basin Gulch project Montana, the Jungo property outside Winnemucca, Nevada, and the Gold Bug Mine in the Company's Southern Oregon operation, comprise the Company's current portfolio. The DGRI management team is composed of seasoned professionals with decades of experience in geology, and in mergers and acquisitions, as well as corporate finance.

About Shamika Gold, Shamika Resources:

Shamika Resources, Inc. holds significant properties in the Democratic Republic of the Congo. The Company is engaged in the development of mineral reserves in Africa. The corporate strategy is to develop a portfolio of mineral companies, unlocking value for shareholders, and opening up multinational access to the capital markets. Shamika Gold Inc. is the second spinoff from Shamika Resources, with additional transactions anticipated in the future.


post #130 of 734
Thread Starter 

apr stop trade order


In connection with the closing of the sale of substantially all of the Company’s assets pursuant to the Second Amended and Restated Asset Purchase Agreement dated February 19, 2010 among the Company, its subsidiaries, and Protective Products Enterprises, Inc., an affiliate of Sun Capital Partners, Inc., the Company and its subsidiaries whose names included the words “Ceramic” or “Protective” were required, at closing, to change their names so that they would not include such words. Accordingly, the Company filed a Certificate of Amendment to its Certificate of Incorporation changing its name to PPOA Holding, Inc. The Certificate of Amendment became effective on March 8, 2010

post #131 of 734
Thread Starter 
Got 300,000 @ .0002

Mar 26, 2010 12:21:14 (ET)

RENO, NV, Mar 26, 2010 (MARKETWIRE via COMTEX) -- PPJ Enterprise (PPJ) (PINKSHEETS: PPJE), a leader in proprietary automated health care reimbursement cycle (all specialties), on line health information digital systems and practice information management digital system software for health care and general businesses worldwide, has announced that its subsidiary, Professional Billing Service (PBS), has signed several medical billing and collection agreements with physicians and surgery centers including 2 former billing clients in the Southern California area. The company forecasts these contracts may yield in excess of $1M in revenue for the company during the first 12 to 18 months.

"These new billing contracts will provide additional milestones for the company's financial health during the year of 2010," noted Chandana Basu (Ms. Basu), CEO of PPJ.

These contracts will bring incremental revenue over extended periods of time and provide consistent cash flow which is dependable and easy to forecast out over multi-year periods. These new contracts also represent high-margin opportunities as our existing overhead allows us to add new contracts with minimal addition to staff or internal expenditures. All our contracts have an initial term of 12 months and renewal for an additional two years. Most of our contracts are renewed after the first year. We are fortunate to be in an industry which is easy to scale and expand without large capital expenditures and is in growing demand. New contracts take approximately 90 to 120 days to see noticeable revenue and these will add to PPJ's bottom line in 3rd quarter of 2010 but significantly by the end of 2010.

"Our marketing team has been working relentlessly on many accounts and expects to close more new billing accounts," noted Ms. Basu, CEO of PPJ.

The Company is also in process of collecting its $4.5M assets from its former client/director.

The Company has added two more former claim processors in the past 30 days to help expedite its collections.

The Company recently was offered to take over outstanding collection accounts with a gross collection of over $50M by its former clients. The Company is offering lower fees to its former clients, and as a result, few have expressed desire to do business with the company in the very near future.

PPJ Enterprise is traded under the symbol PPJE.PK

For more information please contact: PPJ Enterprise Management at (775) 348-5735, website: http://www.ppjenterprise.com/ , email: info@ppjenterprise.com

post #132 of 734
Thread Starter 
More about PPJE

Chandana is currently Chief Operating Officer of PPJ Enterprise (PPJE), and a full-service medical billing services agency in Upland, California. Chandana has been successful in growing HBSGI to generate over $20 million per year in collected billings from a core client base of doctors and hospitals in California, Florida, Washington state and Texas with minimum marketing and advertisement. Chandana Basu's company has been a pioneer in medical bill collecting from insurance companies for over 18 years, and has 14 years of experience in computer design and programming. Chandana is also the CEO and President of AutoMed™ Software Corp. AutoMed™ has pioneered new medical billing software that dramatically decreases inefficiencies in the medical billing process.

“It not only takes an effective medical billing software program, but other consoles are needed to make the medical practice easier to manage such as accounting software links to QuickBooks Pro, automated posting capabilities, and simple patient schedule modules. “ Many of the Automated Biller’s innovation can be credited to Basu’s extensive computer programming experience.

Arjinder Paul Singh Sekhon, M.D. – Director

Dr. Sekhon is a physician licensed in California specialized in pulmonary medicine. He has been a member of the United States Army Reserve for over 20 years; his field experience includes the Persian Gulf War and the current military Operation Enduring Freedom. He has received countless honors from the United States Army for exception patient care and service. During the past congressional election in California, he was a candidate for the U.S. House of Representatives challenging the incumbent Congressman. His professional experience in the United States Army brings much valued direction to this new Director’s role for HBSGI. Dr. Sekhon is a savvy Businessman; he has owned and successfully operated a medical clinic for over 20 years.

Abhijit Bhattacharya, VP/Board of Director

Abhijit Bhattacharya has been affiliated with the Company for over 12 years. In particular, he has connected the Company with several clients, has directed HBSGI’s marketing program, and has promoted the business at various medical conferences throughout the country. Most recently, he has been officially appointed Vice President and is responsible for building new relationships with clients. Mr. Bhattacharya is also a board of Director with the company since March of 2007. Mr. Bhattacharya is a tough and Savvy Businessman in various industries including residential and commercial construction and marketing in the United States for over 30 years. His has successfully managed 100’s of millions of dollars of projects in USA, Middle East and Barbetos.

Payel Madero, COO

Payel Madero, MBA in Health Care Management. She is using this educational background to develop the Automated Biller in terms of achieving and maintaining HIPAA compliance. Currently, she is completing RHIA certification which is sponsored by AHIMA to ensure that Healthcare Administrators understand and enforce HIPAA compliance. The RHIA certification coupled with the continual updates to the Automated Biller will ensure that its users will also be in compliance now and in the future.

Founder’s Objectives

The executives of HBSGI hope that within the next two years, the Automated Biller will be in most of the major markets throughout the country with the assistance of a third party marketing company. At this point, the Automated Biller research and development team will continue to release updates on their software and utilize the most up to date technology available to assist in medical billing management.
post #133 of 734
Thread Starter 
What happened?

The Company is also in process of collecting its $4.5M assets from its former client/director.

I don't think this is what theey meant, what did they mean?-

The Company recently was offered to take over outstanding collection accounts with a gross collection of over $50M by its former clients. The Company is offering lower fees to its former clients, and as a result, few have expressed desire to do business with the company in the very near future
post #134 of 734
I got 3 Mil PPJE at .0002 last I checked LOL.. maybe the entire order filled.. Was too busy at work. I saw the PR thought it may run, then catch some momo.
post #135 of 734
Thread Starter 

IGNT seems to be a massive scam but...

So far the distributors locations have been peoples houses and other even less inspiring locations, an industrial looking farm, around the back of a defunct signless tiny business.
I should check more before I post this but it looks bad.

At least there is a place that says INGEN on the sign.





This last one is http://maconco.com/prod-mr.asp who have been in business since 1977.
A distributor, but I did not see Ingen on their lists.

What is this Macon place or is there something wrong with google maps?

From the Ingen page.
Distribution: Minnesota, North Dakota, South Dakota, Iowa, Nebraska, Kansas, Illinois, Wisconsin, Missouri

Macon & Company, Inc.
4887 North Green Bay Avenue
Milwaukee, WI 53209
Toll Free: 800-537-2859
Local: 414-264-1083
Fax: 414-264-1084
Email: maconj@aol.com

From the Macon site.
Macon & Company, Inc.
4887 North Green Bay Avenue
Milwaukee, WI 53209
Phone: (414) 264-1083
Toll Free: (800) 537-2859
Fax: (800) 319-4960
Voicemail: (800) 535-9512
Email: info@maconco.com

Another company on their site


The address they list is
27822 Fremont Court
Valencia, CA 91355

This is the closest match
27822 Fremont Ct
Newhall, CA 91355

I guess they forgot what city they are in?





Every one of these seems like some kind of scam!

Except- http://www.qosina.com/catalog/search...+Cannula&c=All
This partner doesn't seem to have any of the products I put all the main names and model #s in -but is the only site you probably have to have a real product and credentials for and a little confusing to use..

and this gives some legitimacy- I think,

The BSI certification is legit, so I don't know what is up with the shady addresses.


Certificate FM 558809 was originally issued to "Ingen Technologies " on 15/3/2010.
We can confirm that this is the latest valid issue


Certificate/Licence number:
FM 558809


ISO 13485: 2003

Design and development, manufacture and distribution of oxygen flow mete r for oxygen therapy under respiratory care.

post #136 of 734
Thread Starter 

GFGU .0345

Non-Qualified Stock Optoin (right to buy) 13,000,000 @ $0.04 03/24/2010 Date Exercisable 06/23/2010

GetFugu, Inc. Signs Deal With A Squared (A2) Entertainment To Develop Mobile Applications For Its Influential Brands
Thursday, 25 Mar 2010 08:00am EDT
GetFugu, Inc. announced that it is partnering with A Squared (A2) Entertainment to develop mobile applications, which will be centered around the Getfugu technology. As part of the agreement, Getfugu will develop an interface laced with video, educational and game content currently being produced by A2 Entertainment. Getfugu will provide applications designed for multiple mobile platforms, submit the application to the various platform app stores and manage the backend for the project. - - - - - (repeated)

GetFugu, Inc. And InterKnowlogy To Create Application For Microsoft Windows Phone 7 Series Phones
Tuesday, 16 Mar 2010 08:30am EDT
GetFugu, Inc. announced that it has signed a strategic development agreement with InterKnowlogy (IK), a Microsoft Corp.(R) Gold Certified Partner. InterKnowlogy will create a version of Getfugu's product that runs on Windows Phone 7 Series phones. - - - - - (repeated)

GetFugu, Inc. To Develop Mobile Search Application For Warner Bros. Digital Distribution
Monday, 8 Mar 2010 08:01am EST
GetFugu, Inc. announced that it has signed an agreement with Warner Bros. Digital Distribution (WBDD) to develop and test custom ARL (Augmented Reality Links) and VRL (Voice Recognition Links) to promote five titles using Getfugu's mobile search application. - - - - - (repeated)

GetFugu, Inc. To Provide See It, Say It, Get It Technology
Wednesday, 13 Jan 2010 09:00am EST
GetFugu, Inc. announced that it has entered into an agreement with TapouT, LLC, to provide GetFugu`s See It, Say It, Get It technology to enhance MMA fans` interactive experience on their iPhone, Android and BlackBerry through TapouT`s new MMA mobile center exclusively available on GetFugu.com. TapouT`s MMA mobile center will showcase an innovative and seamless way to purchase TapouT clothing, accessories and gear in real time using GetFugu`s vision, voice and location recognition software. - - - - - (repeated)

GetFugu, Inc. Receives $800,000 in Funding
Tuesday, 29 Dec 2009 09:00am EST
GetFugu, Inc. announced that it has received $800,000 in gross proceeds from the closing of the first tranche of its $10 million financing commitment from Hutton International Investments, Ltd. and the private placement of restricted common stock to an accredited investor at $0.20 per share. - - - - - (repeated)

GetFugu, Inc. Announces $10 Million Financing Commitment
Monday, 14 Dec 2009 09:00am EST
GetFugu, Inc. announced that it has entered into an agreement to receive up to $10,000,000 in funding through a private placement transaction with institutional investor Hutton International Investments, Ltd. The Company may issue one or more tranches of 10% redeemable convertible perpetual preferred stock, or debentures convertible into such preferred stock. - - - - - (repeated)

GetFugu, Inc. Partners With Topps For 'Legends of the Game' Baseball Cards
Monday, 16 Nov 2009 09:00am EST
GetFugu, Inc. announced that it has partnered with The Topps Company, Inc. (Topps), a producer of sports and entertainment trading cards. Topps, the trading card of Major League Baseball, is using GetFugu's 'See It, Say It, Find It, Get It' vision, voice and location recognition services to enhance the 'Legends of the Game' cards in 2009 Topps Baseball Series 1, Series 2 and Updates and Highlights. - - - - - (repeated)

GetFugu, Inc. Announces Appointment Of Chairman And President
Friday, 13 Nov 2009 11:14am EST
GetFugu, Inc. announced that it has appointed several key Directors and Executives to the Board of Directors and senior management team. GetFugu has added five independent Directors to the Board, Michael Jay Solomon as Chairman; and Alan J. Bailey, Donald A. Kurz, Michael J. O' Connor and Chuck Timpe as Directors. GetFugu has added two Executives to its senior management team: Carl Freer as President and Director, and Derek Norton as Chief Operating Officer. - - - - - (repeated)

GetFugu, Inc. Appoints Carl Freer As President-Form 8-K
Friday, 6 Nov 2009 05:29pm EST
GetFugu, Inc. reported in its Form 8-K that Carl Freer, was appointed as President and as a member of Board of Directors effective November 2, 2009

post #137 of 734
Thread Starter 
EROX .13



The Company, a California corporation, was founded in 1989 as EROX Corporation to develop and market a broad range of consumer products containing mood-enhancing compounds containing pheromones or eliciting pheromone like responses. On May 29, 1998, the shareholders of the Company voted to change the name of the Company to Human Pheromone Sciences, Inc. Human Pheromone Sciences, Inc. is alternatively referred to in this report as “we,” “us,” “our,” “HPS” or the “Company”.

The Company believes that research funded by the Company presents an opportunity to create and market new categories of mood-enhancing based consumer products that do not require FDA approval. The Company believes that its related patents provide it a proprietary position in developing, licensing and marketing this category of consumer products.

Replications of naturally occurring compounds, such as pheromones that underlie the Company’s current patents, are chemical substances known to stimulate species-specific biological responses in animals. For nineteen years, scientists and advisors engaged by the Company have studied the functions and characteristics of human pheromones and other mood-enhancing compounds.

The compounds are included as a component of the Company’s current products and are manufactured for the Company by contract vendors. The manufacturing process for these compounds begins with hydrocarbon compounds commonly available from chemical supply houses, and involves the use of a synthetic chemistry process. Since 2001 an independent laboratory has manufactured these compounds, androstadienone and estratetraenol (the “Initial Compounds”), under the direction of HPS’ consulting scientists. All the steps in the manufacturing process are standard chemical laboratory procedures. The manufacturing process for compounds are similar to methods by which other naturally occurring substances (such as amino acids) are synthetically produced.

The Company is also involved in the identification and development of additional compounds that, in initial human studies, have shown a wide spectrum of mood-enhancing activities. In September 2008, the Company filed with the U.S. Patent Office a Comprehensive Patent Application for ER 303 one of the new compounds that it has been testing. The application continues to be under review by the Patent Office.
post #138 of 734
Thread Starter 
The Initial Compounds. People have long known that insects and animals communicate with one another through subtle, biochemical cues recognized and understood by other members of the same species. These biochemical signals warn of danger, indicate the presence of food, mark territorial boundaries and display sexual maturation or readiness. The biochemical messengers that deliver these communications are pheromones. Pheromones trigger (pheromonal response) a nerve impulse to the hypothalamus and other emotion-related centers of the brain when applied within or adjacent to the nasal passages.

Scientists have observed that in higher species the influence of pheromones grows increasingly more subtle and complex. Not surprisingly, reactions to these mood-enhancing compounds are very subtle in human beings. While humans have definite responses to pheromones, the research sponsored by HPS and other scientists suggests that the highly developed human brain filters and masks those reactions. Rather than producing an isolated effect, as in lower level species, these mood-enhancing human pheromones act in concert with other sensory cues provided by odor, sight, taste, sound and touch to provide a cumulative influence.

As a result of its research and the research of other scientists, the Company believes evidence has been developed that indicates that humans respond to these Initial Compounds. HPS has also found that they are sexually dimorphic; that is, some show more activity in females while others show a higher level of activity in males. During the studies of human pheromones conducted by the Company, certain human subjects volunteered descriptions of their feelings. Women frequently described feeling comfortable or at ease or more positive, while a number of male subjects described a feeling of confidence and self-assurance. These results have been independently validated at leading universities around the world.

Consumer Products and the Initial Compounds. Animal pheromones are well known in the consumer products industry. Natural and synthetic equivalents of mammalian pheromones such as musk, civet and castoreum are found in many fragrances today. However, since pheromonal cues can trigger a response only by members of the same species, these animal pheromones have no specific effect on humans; instead, they act only as fixatives or carriers for the fragrance or as a component of the consumer product.

A scent binds to smell receptors in the nose and stimulates a specific region of the brain resulting in the sensation of smell. These Initial Compounds bind to separate receptors that are physically and functionally distinct from smell receptors. These pheromone receptors stimulate a region of the brain different from that stimulated by smell receptors. Since it is widely believed that traditional perfumes and toiletry products allure and intrigue the senses, an alliance between these products and the Company’s compounds seems quite natural. For these products to create a true effect in humans, however, it must contain compounds that will trigger the pheromonal response in humans. Thus, consumer products containing these mood enhancing components may provide more allure than any others currently available.

Additional Compounds. The Company continues to explore naturally occurring substances in a variety of tests to increase its knowledge and understanding of their range of influence on human emotions and their application as components of consumer products. In 2005, the Company began conducting studies on human volunteers with two additional naturally-occurring compounds, ER 303 and ER 99, with positive results. The Company continued to invest in further development of these two additional compounds. In September 2008, the Company filed with the U.S. Patent Office a Comprehensive Patent Application for ER 303 and has begun presenting the benefits of the compound to interested consumer product companies. ER 303 is a previously undeveloped compound with its origin in sea coral, which has positive emotional impacts on both men and women, enhancing feelings of positive social relationships, excitement and social attraction.

With respect to ER 99, which preliminary results have not been made public, the Company is seeking funding for expanded human testing to validate the initial findings. The Company’s six other identified compounds which have completed early stages of development will not have additional testing work performed and minimal development work performed until the financing for such work is available.

The Current HPS Products and Research

Products. The Company began by marketing three fragrances, REALM® Women, REALM® Men and inner REALM®. These “proof-of-concept” products included a full line of fragrance and bath and body products including eau de toilette, cologne, eau de parfume, lotion, bath and shower gel, after-shave balm, deodorant, talc, soap and body cream. In 2003 the Company sold the assets and worldwide ownership rights to the REALM Women, REALM Men and innerREALM product lines, including the rights to all trademarks associated therewith. The proceeds from the sale enabled the Company to focus on developing additional mood-enhancing compounds which it could license and sale to other consumer product companies.

Licensing the use of the Company’s Initial Compounds and related technology is currently the core business of the Company.
post #139 of 734
Thread Starter 
The Company developed a new line of fragrance and toiletry products containing these Initial Compounds for men and women under the trademark Natural Attraction®. The Company distributes these products via www.naturalattraction.com and through distributors both inside and outside the United States. The reference to this Internet website does not constitute incorporation by reference of the information contained on or hyperlinked from this Internet website.

In August 2006, the Company signed an Agreement with Personal Products Company, a division of McNeil-PPC, Inc. (“PPC”) a Johnson & Johnson company. The Agreement with PPC represents a multiple-element arrangement and includes post signing consulting support to PPC as needed to assist them in claims development and manufacturing processes, an exclusive right of first discussion for new compounds that the Company develops and documents supportable claims of effectiveness, and an exclusive right to our existing patented compounds in specific consumer product fields (collectively hereinafter referred to as “PPC Rights”). In exchange for the PPC rights HPS received an initial cash payment and will receive future royalties on sales. The Company retains exclusive rights in several product fields and shares co-exclusive rights in other product areas, with the right to sublicense.

In May 2007, the Company signed an Agreement with Schwarzkopf & Henkel, a division of Henkel Consumer Goods, Inc. and they introduced hair styling products containing our patented compounds.

In June 2009 a second division of Henkel Consumer Goods, Inc., Dial Corporation released a new body wash product line into its retail distribution channel. Also during the year a license agreement was signed for distribution of products containing the Company’s patented compounds in Taiwan and a licensee launched a new product on the Home Shopping Network.

Research. Mood-enhancing compounds, in general, are chemical substances known to stimulate species-specific biological responses in animals. The study of the uses, effects and advantages of human specific compounds is in its infancy, but studies conducted under the Company’s sponsorship as well as several studies conducted by scientists at leading research universities around the world have revealed new information regarding the beneficial effects of the Company’s compounds and the biological pathways these compounds traverse in the human body.

The Research Agreement with the University of Utah, singed on July 13, 2004, to conduct research and provide services expired July 14, 2009. The five year agreement provided that the University will provide professional research and services for specific research programs mutually initiated by the Company and accepted by the University. While the University shall own any inventions and improvements conceived or reduced to practice from the work performed, the Company retains the exclusive option to license any inventions or improvements conceived or reduced to practice and market the products developed from the research results. The Company has the right to develop new compounds outside of this Research Agreement. During the five year period there was no activity undertaken under this agreement.

For the years ended December 31, 2009 and 2008, total research and development expenditures totaled $139,000 and $184,000, respectively. Research expenditures of $54,000 that were incurred in 2009, and $137,000 incurred in 2008, to support the PPC license have been charged as cost of goods sold. The Company expects to continue development efforts, with or without consumer product company(s) as development partners. Since its inception through December 31, 2009, the Company has incurred $6,277,000 in direct research and development related expenses.

Markets and Competition

The Competitive Environment. The Company’s current products contain what the Company believes are unique components: androstadienone and estratetraenol, and a mood-enhancing compound derived from sea coral, ER 303. With these components HPS is able to differentiate its products, and its licensees products, from traditional consumer products. Other than its customers and licensees, the Company believes that no other companies in or outside the United States have the right to produce or distribute products that contain these compounds. However, even with this proprietary technology, the Company and its current customers and licensees are competing against numerous companies including Estee Lauder, Chanel, Proctor and Gamble, Unilever, L’Oreal, and offerings from retailers such as Victoria’s Secret Beauty and Bath and Body Works.
post #140 of 734
Thread Starter 
Got 3333 shares MBTG @ .024

LOS ANGELES, CA--(Marketwire - 03/29/10) - The CEO of Millennium Biotechnologies Group Inc. (OTC.BB:MBTG - News), a product development company for the Clinical Nutrition and Sports Supplement Markets, says his company is at the beginning of their commercialization era and he expects some significant success, "certainly within the next quarter or two."

Mark C. Mirken, President and Chief Operating Officer of Millennium Biotechnologies, Inc., told BioMedReports.Com, the news portal which covers Wall Street's biomedical sector and delivers financial and investment intelligence to a community of highly informed investors, that his company "is now in discusions with two of the largest bottling companies in the world."

According to the exclusive report, as a competitive response to Pepsi's purchase of Muscle Milk for $600 million, one of those major bottling companies is rumored to be close to investing in MBTG in order to help market its Surgex sports drink line as a competitor (to Muscle Milk).

"Our sports product, Surgex, is an independently, medically validated product with a banned substance control group of athletes that is manufactured by us," explains Mirken. "It is used in the NBA and the NFL and its success comes from the work that went into developing it with strength and conditioning coaches and that product is about to have a significant commercial debut which we will announce in the very near future -- predicated on a relationship that we will create with one of the largest powdered drink manufacturers in the world in maximum human performance; which are their customers and which will take us into over 3000 GNC (General Nutrition Centers, Inc.) stores within the next 30 to 60 days. That product will not only launch as a powder, but it will evolve into a functional beverage, ready to drink within 2 to 3 months."

The complete article, which explains several other pending catalysts for the company is available now at BioMedReports.Com:


Biotech investors interested in accessing the news portal's database of clinical trials and upcoming FDA decisions can access that information here:


About BioMedReports.Com

BioMedReports.com is a news portal covering the biomedical news and financial sector. BioMedReports is not paid or compensated to report news and developments about publicly traded companies.

New Posts  All Forums:Forum Nav:
  Return Home
  Back to Forum: Trade Journals & Stock Tips
HotStockMarket › Forums › HSM Stock Forum › Trade Journals & Stock Tips › angrysky's sub penny storm thought share